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Abstract
Background: Clostridium difficile carriage has been considered as a potential source for the deadly infection, but its
role in cancer patients is still unclear. We aimed to identify the clinical and immunological factors that are related to
C. difficile carriage in Chinese cancer patients.
Methods: A total of 400 stool samples were collected from cancer patients who received chemotherapy in three
hospitals of eastern China. Bacterial genomic DNA was extracted and two toxin genes (tcdA and tcdB) were
detected. PCR ribotyping was performed using capillary gel electrophoresis. Concentrations of prostaglandin E2
(PGE2), transforming growth factor beta (TGF-β) and interleukin-10 (IL-10) were measured using enzyme-linked
immunosorbent assay (ELISA) kits.
Results: Eighty-two (20.5%) samples were confirmed to be C. difficile-positive and positive for tpi, tcdA, and tcdB
genes. The C. difficile-positive rates in patients with diarrhea and no diarrhea were 35% and 19.7%, respectively
(p = 0.09). Patients who were younger than 50 years old and were hospitalized for at least 10 days had a
C. difficile-positive rate as high as 35%. In contrast, patients who were older than 50 years old and were hospitalized
for less than 10 days had a C. difficile-positive rate of only 12.7% (p = 0.0009). No association was found between
C. difficile carriage and chemotherapy regimen, antibiotic drug use, or immunosuppressive mediators, such as
prostaglandin E2 (PGE2), transforming growth factor beta (TGF-β), or interleukin-10 (IL-10). Twelve ribotypes of
C. difficile were identified, but none of them belonged to ribotype 027.
Conclusions: We conclude that younger patients and those with longer hospitalization stays may be more prone
to C. difficile carriage. Studies of larger populations are warranted to clarify the exact role of C. difficile carriage in
hospitalized cancer patients in China.
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Background
Clostridium difficile infection is a hospital-acquired infec-
tion, and its prevalence has increased [1]. According to a
report by the U.S. Centers for Disease Control and Pre-
vention in 2013, C. difficile infection has been considered
as an urgent threat and requires immediate attention. The
major risk factors for C. difficile infection include the use
of antibiotics, the use of proton pump inhibitors (PPIs),
hospitalization, aging, and conditions that may affect the
colonic flora [2-5].
It has been reported that cancer patients have a higher
risk for C. difficile infection as compared to noncancer pa-
tients [6]. However, most information currently available
on C. difficile infection is from the non-oncologic popu-
lation. Until now, there is still a lack of comprehensive
epidemiological studies of C. difficile infection in China,
let alone specific investigations on cancer populations.
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Herein, we conducted a comprehensive investigation
on C. difficile carriage in cancer patients from three
hospitals in eastern China. We hoped to identify po-
tential clinical or laboratory factors that are related to
C. difficile carriage in a variety of cancer patients.
Methods
Patients
Samples were collected from cancer centers in three hos-
pitals (The First Affiliated Hospital of Zhejiang University,
Yu-Yao Hospital, and Hu-Zhou Central Hospital). Each
center has about sixty beds and they were expected to
admit more than 1,000 cancer patients in total per year.
All patients provided written consent, and the study
protocol was approved by the Institutional Ethics Com-
mittees of all three hospitals, where samples were
collected. The first stool sample after admission was
collected from each cancer patient. Other information
collected from the patients included the following: time
of sample collection, age, gender, diagnosis, gastro-
enterological surgery within the last 3 months, cumula-
tive days of hospitalization within the last 3 months,
chemotherapy regimen and antibiotic drug use within
the last 3 months, PPI use, diarrhea within the last
3 months, as well as counts of white blood cells and
blood albumin. Medical records were reviewed and pa-
tient interviews were conducted to assess diarrhea
symptoms.
Diarrhea was defined as having three or more loose,
watery stool passages during a 24-h period [7,8]. Diarrhea
was further classified as follows: mild diarrhea, charac-
terized by the absence of signs and symptoms of colitis;
moderate diarrhea, characterized by the presence of col-
itis, fever, and abdominal cramps, usually in the lower
quadrants; and severe diarrhea, defined as colitis asso-
ciated with a leukocyte count greater than or equal to
15,000 cells/l and a serum creatinine level greater than or
equal to 1.5 times the premorbid level [7,8].
Isolates from stool specimens and detection of toxin
genes
All stool specimens were treated with alcohol, and the
mixture was inoculated into cefoxitin-cycloserine fructose
agar (CCFA) plates (Oxoid, Basingstoke) [9]. After incuba-
tion for 48 h at 37°C in a GENbag anaerobic chamber
(BioMérieux, Marcy l’Etoile, France), the isolates were
confirmed to be C. difficile based on assays as previously
described [10]. Bacterial genomic DNA was extracted
using a DNA extraction kit (Qiagen, Inc., Valencia, CA),
according to the manufacturer’s instructions. The house-
keeping gene tpi and the two toxin genes (tcdA and B)
were detected using assays as previously described [9,11].
Amplified products were analyzed by electrophoresis with
ethidium bromide. DNA sequencing of all polymerase
chain reaction (PCR) products was performed according
to standard protocols.
PCR ribotyping
PCR ribotyping was performed using capillary gel electro-
phoresis with primer pairs as described previously [12].
The size of each peak was determined using Genemapper
ID-X software 1.3 (Applied Biosystems). The capillary
sequencer-based PCR-ribotyping data were analyzed using
the WEBRIBO website (https://webribo.ages.at/) [13].
Detection of immunosuppressive mediators
Concentrations of prostaglandin E2 (PGE2; MaiBio,
Shanghai, China), transforming growth factor beta (TGF-β;
Ebioscience, San Diego, CA, USA), and interleukin-10
(IL-10; Ebioscience, San Diego, CA, USA) were measured
using enzyme-linked immunosorbent assay (ELISA) kits.
The ELISA kits were purchased from the above companies,
respectively, and ELISA was carried out according to the
manufactures’ instruction.
Statistical analysis
Statistical analysis was performed by SPSS 20.0 (Chicago,
IL, USA). First, an R × C contingency table was established
to consolidate the quantitative data. The data were then
divided into different groups. The chi-squared test was
used to analyze categorical data. The F-test and T-test
were conducted for hetero or equal variance analysis. Sig-
nificance of variables was determined by univariate Cox
regression analysis (Figure 1). Statistical significance for all
tests was defined as p < 0.05.
Results
A total of 400 samples were collected from April to
October, 2013. The numbers of samples obtained from
Zhejiang University, Yu-Yao, and Hu-Zhou hospitals
were 359, 26, and 15, respectively. There were 259 (65%)
male and 141 (35%) female patients, and the median age
was 57 years old. Further characteristics of the patients
and C. difficile detection outcomes are listed in Table 1.
Among the 82 (20.5%) C. difficile-positive patients, they
were all tcdA and tcdB positive strains (tcdA + and tcdB +)
and no toxin gene-deleted strains (tcdA + and tcdB-, tcdA-
and tcdB+) were identified. All the 20 diarrheal patients
were considered as mild diarrhea. No moderate or severe
diarrhea was identified. The C. difficile-positive rates in
the diarrhea and nondiarrhea patients were 35% and
19.7%, respectively (p = 0.09, as shown in Table 1). No
association was found between the C. difficile-positive rate
and clinical factors, including collection time, sex, diag-
nosis, PPI use, chemotherapy regimen and gastroentero-
logical surgery within the last 3 months, and antibiotic
drug use within the last 3 months.
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Age and C. difficile carriage
The mean ages of the C. difficile-positive and C. difficile-
negative patients were 54 and 56.7 years old, respec-
tively. The T-test showed that the C. difficile infection
rate between these two groups was not significantly dif-
ferent (p = 0.06). Next, the patients were divided into five
consecutive age groups. As shown in Figure 2a, the can-
cer patients in the two age groups of patients who were
younger than 50 years old had a higher infection rate
than the other three groups of patients who were older
than 50 years old. Therefore, 50 years old was set as the
cut-off value and all of the patients were then grouped
into two groups based on this age. The infection rate was
26.9% in the younger group and 18.2% in the older group.
The difference was statistically significant (x2 = 4.17;
p = 0.04).
Cumulative days of hospitalization and C. difficile
carriage rate
Next, it was determined if the cumulative number of days
in hospital was related to the C. difficile positive rate. For
the 318 C. difficile-negative patients, the cumulative
number of days in hospital (within 3 months of sample
collection) was 11.7 days. While for the C. difficile-positive
patients, the cumulative number of days in hospital
was 19.0 days, which was significantly longer (t = 3.5,
p = 0.0005). Further analysis showed that the difference
was more significant when all of the patients were divided
into two groups: hospitalization for 10 days or longer and
less than 10 days. The C. difficile-positive rates were 28.4%
and 13.3%, respectively (x2 = 13.92; p = 0.0002). So, 10 days
of hospitalization was set as the cut-off value for cancer
patients.
Combination of age, days of hospitalization, and
C. difficile-positive rate
Using the two cut-off values of 50 years old and 10 days
of hospitalization, the 400 cancer patients were divided
into four groups and the positive rates of C. difficile in
the various groups were analyzed. As shown in Figure 2b,
Figure 1 Statistical analysis procedure.








Nondigestive tract cancer 172 (43)
Hematological malignancies 32 (8)
C. difficile Carriage Positive 82 (20.5)
Negative 318 (79.5)
Diarrhea Yes 20 (5)
C. difficile-positive 7 (35)#
C. difficile-negative 13 (65)
No 380 (95)
C. difficile-positive 75 (19.7)#
C. difficile-negative 305 (80.3)
#The C. difficile-positive rate was greater in diarrhea patients than in
non-diarrhea patients; however, the difference was not statistically
significant (p = 0.09).
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the positive rate was as high as 35% in patients younger
than 50 years old who were hospitalized for at least
10 days. In contrast, the positive rate was only 12.7% in
patients older than 50 years old who were hospitalized
for less than 10 days. The difference was highly signifi-
cant (x2 = 16.5, p = 0.0009).
PCR ribotyping of the positive strain
The ribotypes of the 82 C. difficile samples were deter-
mined. The results yielded 12 ribotype patterns, including
ribotype 001 (n = 22), ribotype 017 (n = 15), ribotype 017/1
(n = 16), ribotype 014/0 (n = 12), ribotype 017/2 (n = 10),
and one each of ribotypes 666, 650, 555, 445, 220, 037, and
087. None of the strains belonged to ribotype 027.
Immunological indicators and C. difficile-positive rate
The albumin level, white blood cell count, and concentra-
tions of PGE2, TGF-β, and IL-10 are important immuno-
logical indicators for cancer patients. These indicators
were tested for their association with C. difficile carriage.
Figure 2 Association of C. difficile positive rate with different age and hospitalization days. a. Association between C. difficile positive rate
and different age groups. Note: Patients were categorized into five groups of different ages, showing in the figure as positive number/total
number of samples in each group. Patients younger than 50 years old had a significantly higher positive rate than the older groups (p = 0.04).
b. Subdivision of C. difficile positive rate by age and days of hospitalization. Note: Patients were organized into two age groups by the cutoff
value of 50 years old. Each age group was then subdivided into two groups based on the number of days in hospital (≤10 days or >10 days).
*: The C. difficile positive rate was significantly different between the group that was <50 years old and hospitalized >10 days compared to the
group that was≥ 50 years old and hospitalized ≤10 days (35.0% vs. 12.7%, p = 0.0009).
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All of the factors, including white blood cell count, albu-
min count, PGE2, TGF-β, and IL-10 concentrations, were
not significantly different between the C. difficile-positive
and negative patients.
Discussion
In this study, we conducted a comprehensive investiga-
tion of C. difficile carriage among cancer patients from
three hospitals in eastern China. The overall C. difficile-
positive rate of the cancer patients enrolled in the
7-month period was 20.5%. This rate is much higher than
that (12.6%) reported in non-cancer patients in a similar
study in 2009 in eastern China [14]. The relationship
between various clinical and immunological factors and
C. difficile carriage was further analyzed. Two factors (age,
days of hospitalization) were determined to be signifi-
cantly associated with the rate of C. difficile carriage. First,
we found that cancer patients with C. difficile carriage ap-
peared to be younger than patients from the U.S. [15].
This difference could be caused by various factors, such as
diet, geographical location, intake of food supplements
and drugs, and other causes. Studies also have found that
features of gut microbiomes are always unique to different
locations and lifestyles [16]. The lifestyles of Chinese
people, especially those of young Chinese, have changed
dramatically over the last 20 years, partially because of the
rapid growth of the Chinese economy. The changed life-
style which was not so common in China in the past,
might be a major contributor to the increasing emergence
of C. difficile infection. Interestingly, the age predis-
position was consistent with a previous study of cancer
patients in Beijing, China [17]. Meanwhile, a large scale
study in Japan also revealed that long hospital stay was
associated with C. difficile infection [18]. However, these
two studies did not provide a cutoff value for age and the
hospitalization days. In our study, we found that the can-
cer patients who were younger than 50 years old and had
stayed in hospital for more than 10 days were more prone
to C. difficile carriage. It is easier to understand that lon-
ger stay in hospital exposes a higher risk of infection to
patients; it is less clear to us why the younger patients in
our study were more prone to C. difficile carriage. A simi-
lar result was reported recently in northern China [17].
Immune response is important for C. difficile carriage.
However, among white blood cell count, albumin count,
and levels of PGE2, TGF-β, and IL-10, which are
thought to be inhibitors of immunological activity [19],
we found no factor was related to the C. difficile-positive
rate. And ribotyping of C. difficile showed that there was
no 027 strain, which was the major cause of the deadly
C. difficile infection emergence in Canada between 2002
and 2005 [20].
Strikingly, more than 90% of the C. difficile-positive can-
cer patients in our study had no symptoms of diarrhea.
The reason might be complicated. A similar study
also showed no outbreak of C. difficile infection despite
C. difficile carriage [21]. Nevertheless, researchers have
suggested that asymptomatic carriers can contribute to
C. difficile transmission in hospitals [22]. As a result of the
near-indefinite viability of the bacteria and the low infec-
tive dose, C. difficile could be widely transmitted within
hospitals in the presence of the ever increasing asympto-
matic carriers [23].
Conclusions
In our current study, no cancer-specific factors were iden-
tified to be related to C. difficile carriage. However, a
younger age and a longer hospitalization stay may repre-
sent the characteristics of more aggressive and immu-
nosuppressive oncologic disease. Larger sample size and
cancer-specific information mining research is needed in
the future in order to clarify the exact role of C. difficile
carriage in cancer patients.
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